Single-component self-assembled RNAi nanoparticles functionalized with tumor-targeting iNGR delivering abundant siRNA for efficient glioma therapy

Biomaterials

Volumn 53, Issue , 2015, Pages 330-340

  An, Sai ^a   Jiang, Xutao ^a   Shi, Jiashu ^a   He, Xi ^a   Li, Jianfeng ^a   Guo, Yubo ^a   Zhang, Yu ^a   Ma, Haojun ^a   Lu, Yifei ^a   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Glioma therapy; Glutathione triggered; INGR; RNAi; Self assembled nanoparticle; Tumor homing and penetrating

Indexed keywords

NANOPARTICLES; NANOSPHERES; PEPTIDES; SULFUR COMPOUNDS; SYNTHESIS (CHEMICAL);

GLIOMA THERAPY; GLUTATHIONES; INGR; RNAI; SELF ASSEMBLED NANOPARTICLES;

TUMORS;

CYCLOPEPTIDE; CYCLOPEPTIDE INGR; GLUTATHIONE; MICROSOMAL AMINOPEPTIDASE; NANOPARTICLE; NRP 1 PROTEIN; POLYCATION; SELF ASSEMBLED RNAI NANOPARTICLE; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG; CYSTEINYL-ARGINYL-ASPARAGYL-GLYCYL-ARGINYL-GLYCYL-PROLYL-ASPARTYL-CYSTEINE; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; CHEMISTRY; MALE; NUDE MOUSE; OXIDATION REDUCTION REACTION;

ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; OXIDATION-REDUCTION; RNA INTERFERENCE;

EID: 84927920630     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.084     Document Type: Article

References (45)

1. Yan R., Hallam A., Stockley P.G., Boyes J. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy. Biochem J 2014, 461:1-13.
2. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
3. Lee J.M., Yoon T.J., Cho Y.S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int 2013, 2013:782041.
4. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
5. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012, 7:3637-3657.
6. Lee J.B., Hong J., Bonner D.K., Poon Z., Hammond P.T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012, 11:316-322.
7. Zhdanov R.I., Podobed O.V., Vlassov V.V. Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry 2002, 58:53-64.
8. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
9. Amaduzzi F., Bomboi F., Bonincontro A., Bordi F., Casciardi S., Chronopoulou L., et al. Chitosan-DNA complexes: charge inversion and DNA condensation. Colloids Surf B Biointerfaces 2014, 114:1-10.
10. Wang R., Zhou L., Zhou Y., Li G., Zhu X., Gu H., et al. Synthesis and gene delivery of poly(amido amine)s with different branched architecture. Biomacromolecules 2010, 11:489-495.
11. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm Res 2009, 26:235-243.
12. Yu H., Russ V., Wagner E. Influence of the molecular weight of bioreducible oligoethylenimine conjugates on the polyplex transfection properties. AAPS J 2009, 11:445-455.
13. Cheng G., He Y., Xie L., Nie Y., He B., Zhang Z., et al. Development of a reduction-sensitive diselenide-conjugated oligoethylenimine nanoparticulate system as a gene carrier. Int J Nanomedicine 2012, 7:3991-4006.
14. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. JNutr 2004, 134:489-492.
15. Shao K., Ding N., Huang S., Ren S., Zhang Y., Kuang Y., et al. Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. ACS Nano 2014, 8:1191-1203.
16. Giordano S.H., Temin S., Kirshner J.J., Chandarlapaty S., Crews J.R., Davidson N.E., et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American society of clinical oncology clinical practice guideline. JClin Oncol 2014, 32:2078-2099.
17. Rangger C., Helbok A., von Guggenberg E., Sosabowski J., Radolf T., Prassl R., et al. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Int J Nanomedicine 2012, 7:5889-5900.
18. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002, 2:83-90.
19. Kuroki M., Shirasu N. Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res 2014, 34:4481-4488.
20. Ryu J.H., Koo H., Sun I.C., Yuk S.H., Choi K., Kim K., et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev 2012, 64:1447-1458.
21. Alberici L., Roth L., Sugahara K.N., Agemy L., Kotamraju V.R., Teesalu T., et al. De novo design of a tumor-penetrating peptide. Cancer Res 2013, 73:804-812.
22. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002, 62:867-874.
23. Corti A., Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol 2011, 12:1128-1134.
24. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006, 63:2968-2978.
25. Roth L., Agemy L., Kotamraju V.R., Braun G., Teesalu T., Sugahara K.N., et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012, 31:3754-3763.
26. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
27. Tijsterman M., Ketting R.F., Plasterk R.H. The genetics of RNA silencing. Annu Rev Genet 2002, 36:489-519.
28. Sarah L., Daubendiek K.R., Eric T.K. Rolling-circle RNA synthesis: circular oligonucleotides as efficient substrates for T7 RNA polymerase. JAm Chem Soc 1995, 117:7818-7819.
29. Seyhan A.A., Vlassov A.V., Johnston B.H. RNA interference from multimeric shRNAs generated by rolling circle transcription. Oligonucleotides 2006, 16:353-363.
30. Guo P. The emerging field of RNA nanotechnology. Nat Nanotechnol 2010, 5:833-842.
31. Tong A.W., Jay C.M., Senzer N., Maples P.B., Nemunaitis J. Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr Gene Ther 2009, 9:45-60.
32. Liu L., Xu K., Wang H., Tan P.K., Fan W., Venkatraman S.S., et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009, 4:457-463.
33. Lee J.S., Green J.J., Love K.T., Sunshine J., Langer R., Anderson D.G. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009, 9:2402-2406.
34. Elbakry A., Zaky A., Liebl R., Rachel R., Goepferich A., Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett 2009, 9:2059-2064.
35. Kirsanov K.I., Lesovaya E.A., Yakubovskaya M.G., Belitsky G.A. SYBR Gold and SYBR Green II are not mutagenic in the Ames test. Mutat Res 2010, 699:1-4.
36. Tijsterman M., Plasterk R.H. Dicers at RISC; the mechanism of RNAi. Cell 2004, 117:1-3.
37. Lee S.J., Huh M.S., Lee S.Y., Min S., Lee S., Koo H., et al. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew Chem Int Ed Engl 2012, 51:7203-7207.
38. Suschke H.J., Bender-Götze C., Brosse J., Kunze D., Rosendahl C., Walther U. Cell membrane differences between malignant and nonmalignant cells. Monatsschr Kinderheilkd 1985, 133:891-893.
39. Stace T.M., Damiano E.R. An electrochemical model of the transport of charged molecules through the capillary glycocalyx. Biophys J 2001, 80:1670-1690.
40. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000, 60:722-727.
41. Guzman-Rojas L., Rangel R., Salameh A., Edwards J.K., Dondossola E., Kim Y.G., et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA 2012, 109:1637-1642.
42. Huang S., Shao K., Liu Y., Kuang Y., Li J., An S., et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013, 7:2860-2871.
43. Wei T., Liu J., Ma H., Cheng Q., Huang Y., Zhao J., et al. Functionalized nanoscale micelles improve drug delivery for cancer therapy invitro and invivo. Nano Lett 2013, 13:2528-2534.
44. Toy R., Peiris P.M., Ghaghada K.B., Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the invivo journey of nanoparticles. Nanomedicine Lond 2014, 9:121-134.
45. Hochgräfe K., Mandelkow E.,M. Making the brain glow: invivo bioluminescence imaging to study neurodegeneration. Mol Neurobiol 2013, 47:868-882.